|1.||Barsoum, James: 3 articles (02/2012 - 10/2008)|
|2.||Ying, Weiwen: 3 articles (02/2012 - 10/2008)|
|3.||Foley, Kevin P: 3 articles (02/2012 - 10/2008)|
|4.||Sang, Jim: 2 articles (02/2012 - 11/2010)|
|5.||Blackman, Ronald K: 2 articles (02/2012 - 11/2010)|
|6.||Du, Zhenjian: 2 articles (02/2012 - 10/2008)|
|7.||Proia, David A: 2 articles (02/2012 - 11/2010)|
|8.||Inoue, Takayo: 1 article (02/2012)|
|9.||Ye, Shuxia: 1 article (02/2012)|
|10.||Ogawa, Luisa Shin: 1 article (02/2012)|
|1.||Breast Neoplasms (Breast Cancer)
01/01/2012 - "17-allylamino,17-demethoxygeldanamycin is the first Hsp90 inhibitor that has clinically been investigated in phase II trial, yielding promising results in patients with HER2-overexpressing metastatic breast cancer, whilst other Hsp90 inhibitors (retaspimycin HCL, NVP-AUY922, NVP-BEP800, CNF2024/BIIB021, SNX-5422, STA-9090, etc.) are currently under evaluation. "
02/01/2012 - "Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 that is currently in clinical trials for a number of human cancers. "
12/01/2010 - "STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer."
10/01/2008 - "The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors."
12/01/2010 - "Moreover, administration of STA-9090 led to significant tumor shrinkage in several tumor xenograft models in mice and appeared to be less toxic. "
12/01/2010 - "Furthermore STA-9090 demonstrated better tumor penetration compared with tanespimycin. "
|4.||Wilms Tumor (Wilm's Tumor)
12/01/2010 - "STA-9090 binds to the ATP-binding domain at the N-terminus of Hsp90 and acts as a potent Hsp90 inhibitor by inducing degradation of multiple oncogenic Hsp90 client proteins including HER2/neu, mutated EGFR, Akt, c-Kit, IGF-1R, PDGFRα, Jak1, Jak2, STAT3, STAT5, HIF-1α, CDC2, c-Met, and Wilms' tumor 1. STA-9090, at low nanomolar concentrations, potently arrested cell proliferation and induced apoptosis in a wide variety of human cancer cell lines, including many receptor tyrosine kinase inhibitor- and tanespimycin-resistant cell lines. "
|5.||Myeloid Leukemia (Leukemia, Myelocytic)
|1.||6- chloro- 9- (4- methoxy- 3,5- dimethylpyridin- 2- ylmethyl)- 9H- purin- 2- ylamine
|2.||Proteins (Proteins, Gene)
|5.||Adenosine Triphosphate (ATP)
|6.||tyrosine receptor (receptor, tyrosine)
|1.||Heterologous Transplantation (Xenotransplantation)